Diabetes Management - CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Diabetes and Endocrinology Specialist's Perspective

Skip to main content

Latest Videos |view all videos

Showing 13 - 24 of 27 results

Previous| 1 | 2 | 3 |Next

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

To what degree have you observed statin intolerance or resistance in patients with high risk CAD? What protocol do you employ to mitigate and/or manage statin intolerance? Where does the PCSK9 inhibitor fit into your sequencing strategy?

To what degree have you observed statin intolerance or resistance in patients with high risk CAD? What protocol do you employ to mitigate and/or manage statin intolerance? Where does the PCSK9 inhibitor fit into your sequencing strategy?

From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels <70 mg/dL with PCSK9 inhibitors? And in which patient subgroups do these agents offer unique outcome-related benefits?

From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels <70 mg/dL with PCSK9 inhibitors? And in which patient subgroups do these agents offer unique outcome-related benefits?

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

In the Type 2 diabetes population that you manage in your, what percentage of patients do you estimate do not achieve risk-appropriate LDL-C for any number of reasons? Is it as high as 10%, as reported in by some diabetes experts?

In the Type 2 diabetes population that you manage in your, what percentage of patients do you estimate do not achieve risk-appropriate LDL-C for any number of reasons? Is it as high as 10%, as reported in by some diabetes experts?

What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?

What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?

Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL?

From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?

From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?

Given that ODYSSEY Outcomes has shown not only reduction in CV events, but also a reduction in associated, all-cause mortality, what is the role of PCSK9 inhibitors in diabetes patients with a prior ACS event?

Given that ODYSSEY Outcomes has shown not only reduction in CV events, but also a reduction in associated, all-cause mortality, what is the role of PCSK9 inhibitors in diabetes patients with a prior ACS event?

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

Which patients, in your view, are not candidates for PCSK9 inhibition?

Which patients, in your view, are not candidates for PCSK9 inhibition?

When is 70 mg/dL not good enough? Is this a threshold? What clinical factors suggest lower targets are better? What is happening at the vascular biology level?

When is 70 mg/dL not good enough? Is this a threshold? What clinical factors suggest lower targets are better? What is happening at the vascular biology level?

Showing 13 - 24 of 27 results

Previous| 1 | 2 | 3 |Next